KRAS inhibitor combinations for improved therapeutic efficacy

DISEASE CATEGORY: Cancer

INDICATION: Lung cancer, pancreatic cancer

UCSF’s Kevan Shokat and colleagues have identified two sets of genes for which inhibition could improve the efficacy of KRAS G12C inhibitors. Through a CRISPR-based screen in human lung and pancreatic cancer cells treated with a KRAS G12C inhibitor tool compound for genes

Read the full 498 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE